Peptidomimetic research compound · Fact sheet
Dihexa
Also known as PNB-0408 · Dihexa acetate
Dihexa is an experimental peptidomimetic studied for nerve-cell signaling and cognition in laboratory models. It has no established human cognitive benefit or FDA-approved use, and human safety information is inadequate.
What is Dihexa?
Dihexa is derived from angiotensin-related peptide research and interacts with hepatocyte growth factor signaling through c-Met. It is distinct from other compounds developed around the same pathway.
Benefits people look for
Memory, learning, and brain repair are common claims. New synaptic connections in a laboratory system do not show that a person will think better or recover from a neurological disease.
What the evidence supports
- Preclinical work links Dihexa to synapse-related changes and animal learning measures.
- Protective effects in zebrafish sensory hair cells provide an additional research question, not a clinical indication.
All research areas
- HGF/c-Met signaling
- Synaptic plasticity
- Experimental cognition
- Hair-cell protection models
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- FDA reports no identified human exposure data and major safety-information gaps.
- Effects on a cell-growth signaling pathway require safety evaluation; the mechanism alone cannot establish or exclude cancer risk.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchThe central cognition findings come from cell and animal experiments. A separate zebrafish hair-cell study is a different biological model, not evidence of improved human hearing or cognition.
Selected research to read
Mechanistic and animal cognition experiments.
Preclinical protection model, not a human clinical outcome.
FDA approval & research status
Dihexa has no FDA-approved therapeutic use. FDA identifies a lack of human exposure information in its dihexa acetate assessment.
No FDA-approved use is documented in the records summarized on this page.
Preclinical research; no FDA approval
Dihexa has no FDA-approved therapeutic use. FDA identifies a lack of human exposure information in its dihexa acetate assessment.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Human cognitive benefit
- Human metabolism and interactions
- Long-term neurological and cell-growth effects
The takeaway
Dihexa remains a preclinical research topic; confident claims of human cognitive enhancement exceed the available evidence.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- 2
- 3pubmedDihexa in zebrafish sensory hair cells
Preclinical protection model, not a human clinical outcome.